← Eichor
Study identifier: NCT02670707 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

Condition: Langerhans Cell Histiocytosis  ·  Sponsor: Baylor College of Medicine

PhasePhase 3
Planned participants124
Who can joinAll sexes, N/A to 21 Years
Healthy volunteersNo

About this study

Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body, where they can damage tissue or form lesions. For most patients with LCH, standard-of-care vinblastine/prednisone are used as front-line therapy while cytarabine therapy has been used as therapy for patients who develop recurrence. No alternate treatment strategy has been developed for frontline therapy in LCH. The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH. We will evaluate the utility of an imaging study called a positron emission tomography (PET) scan to more accurately assess areas of LCH involvement not otherwise seen in other imaging studies as well as response to therapy. We also want to identify if genetic and other biomarkers (special proteins in patient's blood and in patient's cancer) relate to the response of patients LCH to study treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Olive Eckstein, MD  ·  832-822-4242  ·  Eckstein@bcm.edu

Carl E. Allen, MD, PhD  ·  832-826-0860  ·  ceallen@txch.org

Always discuss trial participation with your own doctor first.

Locations (11)

Stanford Children's Hospital, Lucile Packard Children's HospitalPalo Alto, California, United StatesRecruiting
Rady Children's Hospital - San DiegoSan Diego, California, United StatesRecruiting
University of Minnesota/Masonic Cancer CenterMinneapolis, Minnesota, United StatesWithdrawn
Nationwide Children's HospitalColumbus, Ohio, United StatesRecruiting
Lehigh Valley Health Network- Cedar CrestAllentown, Pennsylvania, United StatesRecruiting
Dell Children's Medical CenterAustin, Texas, United StatesRecruiting
Cook Children's Health Care SystemFort Worth, Texas, United StatesRecruiting
Texas Children's HospitalHouston, Texas, United StatesRecruiting
Vannie Cook Children's ClinicMcAllen, Texas, United StatesRecruiting
Children's Hospital of San AntonioSan Antonio, Texas, United StatesRecruiting
Children's Hospital of The King's DaughtersNorfolk, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02670707